Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dementia01:30

Dementia

482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

JAMA·2026
Same author

Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases.

Neurology·2026
Same author

Digital Cognitive Phenotyping for Differential Diagnosis and Monitoring in Neurological Conditions.

Annals of clinical and translational neurology·2026
Same author

Profiling Protein Aggregate Size Using Single-Molecule Array Technology.

Analytical chemistry·2026
Same author

Not Lost in Translation: Universality of Clinical-Pathobiologic Correlation in Alzheimer Disease.

Neurology·2026
Same author

Cortical synchrony is reduced in Alzheimer's disease and relates to arousal state.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

相关实验视频

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K

技术与痴呆症 会议前会议

Josh King-Robson1, Eyal Soreq2,3,4, Molly R E Cartlidge1

  • 1Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
概括

数字睡眠生物标志物在早期发现阿尔茨海默病病理学方面表现有前途. 一个使用床下传感器的新型模型识别了具有显著tau病理的个体,可与血液测试相比较.

更多相关视频

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

相关实验视频

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

科学领域:

  • 神经学 神经学
  • 生物标志物发现发现
  • 老年学是指老年学的学科.

背景情况:

  • 睡眠和昼夜干扰与痴呆症风险增加有关.
  • 数字睡眠生物标志物为远程查初始痴呆症提供了一种低负担的方法.
  • 这项研究探讨了使用Withings睡眠分析仪 (WSA) 来检测与阿尔茨海默病相关的生物标志物.

研究的目的:

  • 评估使用数字睡眠生物标志物用于痴呆症查的可行性.
  • 为了确定基于WSA的数字睡眠生物标志物对阿尔茨海默病理学的预测价值.
  • 为了比较睡眠生物标志物的表现与化的 (pTau) 217.7.

主要方法:

  • 洞察46研究的参与者接受了连续评估,包括粉样蛋白和蛋白PET扫描.
  • 威廷斯睡眠分析仪 (WSA) 收集了连续睡眠,昼夜和生理数据.
  • 使用"一次排除"的交叉验证方法来开发PET状态的预测模型.

主要成果:

  • 总共有63,720个夜晚的睡眠数据从161名参与者收集了WSA和Tau PET数据.
  • 一个训练有素的模型识别了患有Braak3+ tau病理的个体,AUROC为0.75.
  • 该模型的性能与血pTau217可比,但对于早期的病理阶段效果较差.

结论:

  • 在老年人群中,通过像WSA这样的设备进行远程睡眠和昼夜监测是可行的.
  • 一个数字睡眠生物标志物模型显示了识别显著tau病理的潜力,类似于血pTau217.
  • 这项研究提供了使用数字睡眠生物标志物来识别临床阿尔茨海默病高风险个体的概念证明.